keep away from direct sunlight,store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NecroX-7 (LC-280126) is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. Additionally, NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 may be use for treatment of graft-versus-host disease (GVHD) research [1].
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 12,000 | |||
5 mg | 在庫あり | ¥ 28,000 | |||
10 mg | 在庫あり | ¥ 45,500 | |||
25 mg | 在庫あり | お問い合わせ | |||
50 mg | 在庫あり | お問い合わせ |
説明 | NecroX-7 (LC-280126) is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. Additionally, NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 may be use for treatment of graft-versus-host disease (GVHD) research [1]. |
In vitro | NecroX-7, at concentrations ranging from 0 to 40 μM and incubated for 3-4 days, effectively suppresses the activation and proliferation of T cells without inducing apoptosis, as demonstrated in a study [1]. Additionally, this compound significantly reduces high-mobility group box 1 (HMGB1) levels in a dose-dependent manner and inhibits the generation of mitochondria-specific reactive oxygen species (ROS) and reactive nitrogen species in H9C2 cardiac cells and hepatocytes, triggered by tert-butyl hydroperoxide or doxorubicin [1]. Moreover, NecroX-7 has been shown to increase the numbers of regulatory T cells, suggesting its potential role in the modulation of differentiation signals that are independent of HMGB1 effects [1]. In a cell proliferation assay utilizing CD4 T cells across a gradient of 0 to 40 μM concentrations over 3-4 days, a significant decline in splenocyte proliferation was observed, indicating its effectiveness in modulating alloreactive T cell responses in a dose-dependant manner [1]. |
In vivo | NecroX-7 (0-0.3 mg/kg, IV, once injection at 2-day intervals for 2 weeks) significantly reduces graft-versus-host disease (GVHD)-related mortality and severe tissue damage. It offers protection in mice against lethal GVHD through the reciprocal regulation of regulatory T/Th1 cells, reduces systemic High Mobility Group Box 1 (HMGB1) levels, and mitigates HMGB1-mediated inflammation. In an animal model involving female BALB/c and C57BL/6 mice (eight-week-old, with GVHD), dosages of 0.03, 0.1, and 0.3 mg/kg administered intravenously at two-day intervals for two weeks resulted in notable improvements. Statistically significant increases in survival rates were observed with doses ≥0.1 mg/kg, where 30–60% of treated mice survived for over 50 days. Additionally, treated mice exhibited significantly fewer clinical signs of acute GVHD, including reductions in weight loss, hunched posture, diarrhea, and ruffled fur, indicating an overall improvement in health and extended survival. |
別名 | LC-280126, LC28-0126, LC28 0126 |
分子量 | 439.57 |
分子式 | C24H29N3O3S |
CAS No. | 1120332-55-9 |
keep away from direct sunlight,store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
NecroX-7 1120332-55-9 Immunology/Inflammation NADPH-oxidase LC 280126 NecroX7 LC-280126 NecroX 7 LC28-0126 LC280126 LC28 0126 Inhibitor inhibitor inhibit